Unblocking Barriers of Access to Hepatitis C Treatment in China: Lessons Learned from Tianjin
Background: The high price is a critical barrier of access to new direct-anting-antiviral (DAA) therapies for hepatitis C for both the patients and the society. Many countries continue to face the challenge of financing such expensive medicines. Such examples include both high-income and middle-inco...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Ubiquity Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a6f2448d5e6a4a14a56c60a6e6a57089 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|